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. X-ray crystal structure of retrofragment 3 in complex with CYP121 (pg. S2) Figure S2 . Docking results for 14b overlaid with X-ray crystal structure of 5 (pg. S2) Figure S3 . X-ray crystal structures of CYP121 in complex with 25a (pg. S3) Figure S4 . X-ray crystal structures of CYP121 in complex with 24a and 25a (pg. S3) Table S1 . CYP121-ligand binding stoichiometry determined by NanoESI (pg. S4) Table S2 . Effect of ligand binding on CYP121 oligomerisation (pg. S4) Table S3 . IC50 values of known inhibitors of human drug-metabolising P450s (pg. S5) Table S4 . Cellular activity of CYP121 ligands (pg. S5) Table S5 . X-ray crystallography data collection and refinement statistics (pg. S6) Figure S5 . Omit Fo-Fc electron density maps of CYP121 ligands (pg. S8) References (pg. S9) Figure S1 . X-ray crystal structure of retrofragment 3 (olive) in complex with CYP121. Inset: Omit Fo-Fc electron density map of 3 (yellow) contoured to 3σ. Active site residues (blue lines), heme cofactor (magenta sticks) and potential hydrogen bonds (yellow dashes) to active site water molecules have been indicated. Figures prepared using PyMOL v1.7.4 (Schrödinger, LLC). . Docking results for Ar1 analogue 14b overlaid with the X-ray crystal structure of retrofragment 5 (yellow) in complex with CYP121 (PDB 4KTF). 1 Predicted hydrogen bonding interactions (yellow dashes) between 14b and active site residues (blue lines) and water molecules (red spheres) have been illustrated. Amino acid Asn85 appears in the lower left corner of the figure. Docking was performed using GLIDE v6.5 (Schrödinger, LLC, New York, NY). . X-ray crystal structures of CYP121 in complex with 25a (orange) (PDB 5IBE) overlaid with the X-ray crystal structures of CYP121 in complex with aniline fragments 8 (copper) (PDB 4G44) and 9 (cyan) (PDB 4G45). 2 Retrofragment 5 (yellow) (PDB 4KTF) 1 has also been included to illustrate the shift in the position of the 5-aminopyrazole ring that occurred as a result of removing the 4-hydroxy substituent from Ar2 to optimise heme-binding interactions. Figure S4 . X-ray crystal structures of CYP121 in complex with analogue 24a (grey sticks) (PDB 5IBD) overlaid with 25a (orange lines) (PDB 5IBE). The identical binding position of the two analogues illustrates tolerance of the Ar1 site to the 4-methyl protecting group retained in analogue 24a. Table S1 . CYP121-ligand binding stoichiometry determined by native mass spectrometry. Native mass spectra were collected for CYP121 (5-8.7 μM) in the presence of ligands at 3 different protein-to-ligand ratios (2.5-125 μM ligand). Ligand binding stoichiometry was calculated from the difference in mass of ligand-bound and unbound protein peaks divided by the molecular weight of ligands. All spectra were collected in the presence of 2.18-5% v/v d6-DMSO. Binding affinities (KD values) were determined by UV-Vis optical titration for Ar2 heme-binding analogues. Isothermal titration calorimetry (ITC) was also used to determine the KD values of all analogues, except 24a which had low solubility.
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KD (μM) Table S4 . Cellular activity of CYP121 ligands. The concentration of CYP121 ligands required to kill 90% of cells in Mtb H37Rv cultures relative to DMSO controls was determined in triplicate over a 6 point concentration range between 0-100 μM. Compounds 14c and 29c were included as negative controls because of their weak CYP121 binding affinity (see Table 2 ). Rifampicin was included as a positive control and was tested between 0-0.18 μM. "N" indicates that compounds did not produce any significant cell death within the tested concentration range. Figure S5 (a-i) . Omit Fo-Fc electron density maps (green mesh) contoured to 3σ for ligands 3, 6, 7, 19a, 24a, 25a, 25b, 26a and 26h (yellow sticks) respectively, from X-ray crystal structures of ligands in complex with CYP121. 19a 5IBF 24a 5IBD 25a 5IBE 25b 5IBG 26a 5IBI 26h 5IBH
